Douglas Earl Martin
SVP, General Counsel
Douglas Earl Martin has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 25, 2026.
On the most recent filing, Douglas Earl Martin is listed as SVP, General Counsel at Allogene Therapeutics, Inc. Inside the rolling window, Douglas Earl Martin reported no open-market purchases and 2 open-market sales totaling $103K in ALLO. The largest disclosed transaction in the window is a sale of 29,697 ALLO shares on Aug 21, 2026, worth $63K.
Companies traded
Other insiders at ALLO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$103K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Douglas Earl Martin made?
Douglas Earl Martin has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Douglas Earl Martin trade?
Douglas Earl Martin has filed SEC Form 4 disclosures for 1 company, including ALLO.
When was Douglas Earl Martin's most recent SEC Form 4 filing?
Douglas Earl Martin's most recent SEC Form 4 filing on Tracefour is dated Aug 25, 2026.
What is Douglas Earl Martin's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Douglas Earl Martin is listed as SVP, General Counsel.
What is Douglas Earl Martin's total buy and sell value in the current window?
Inside the rolling retention window, Douglas Earl Martin bought $0 and sold $103K based on SEC Form 4 filings.
What was Douglas Earl Martin's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 29,697 ALLO shares on 2026-08-21, worth $63K, per SEC Form 4 filings.